To assess whether disulfS can guide immunotherapy and drug therapy in clinical HCC patients, we analyzed the IPS of two ICIs, anti PD-1 and anti CTLA-4, using TCIA data. The gene discussed is CTLA4; the disease is hepatocellular carcinoma.